Perioperative durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable gastric and gastro-oesophageal junction adenocarcinoma (MATTERHORN): final results of overall survival and event-free survival by pathological response in a global, randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.

Janjigian YY, Al-Batran SE, Wainberg ZA, Muro K, Molena D, Van Cutsem E, Hyung WJ, Wyrwicz L, Oh DY, Omori T, Moehler M, Bragagnoli AC, Garbaos G, Liberman M, Mirón MLL, Smyth EC, Cheng LY, Robbins SH, Valeri N, Xynos I, Tabernero J, MATTERHORN investigators

Open source

DOI: 10.1016/s0140-6736(26)01254-7
Published: 2026 Sep 19
Container: Lancet (London, England)
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s0140-6736-26-01254-7,
  title = {Perioperative durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable gastric and gastro-oesophageal junction adenocarcinoma (MATTERHORN): final results of overall survival and event-free survival by pathological response in a global, randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.},
  author = {Janjigian YY and Al-Batran SE and Wainberg ZA and Muro K and Molena D and Van Cutsem E and Hyung WJ and Wyrwicz L and Oh DY and Omori T and Moehler M and Bragagnoli AC and Garbaos G and Liberman M and Mirón MLL and Smyth EC and Cheng LY and Robbins SH and Valeri N and Xynos I and Tabernero J and MATTERHORN investigators},
  year = {2026},
  journal = {Lancet (London, England)},
  doi = {10.1016/s0140-6736(26)01254-7},
  url = {https://doi.org/10.1016/s0140-6736(26)01254-7}
}

RIS

TY  - JOUR
TI  - Perioperative durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable gastric and gastro-oesophageal junction adenocarcinoma (MATTERHORN): final results of overall survival and event-free survival by pathological response in a global, randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
AU  - Janjigian YY
AU  - Al-Batran SE
AU  - Wainberg ZA
AU  - Muro K
AU  - Molena D
AU  - Van Cutsem E
AU  - Hyung WJ
AU  - Wyrwicz L
AU  - Oh DY
AU  - Omori T
AU  - Moehler M
AU  - Bragagnoli AC
AU  - Garbaos G
AU  - Liberman M
AU  - Mirón MLL
AU  - Smyth EC
AU  - Cheng LY
AU  - Robbins SH
AU  - Valeri N
AU  - Xynos I
AU  - Tabernero J
AU  - MATTERHORN investigators
PY  - 2026
JO  - Lancet (London, England)
DO  - 10.1016/s0140-6736(26)01254-7
UR  - https://doi.org/10.1016/s0140-6736(26)01254-7
ER  -

APA

YY, J., SE, A., ZA, W., K, M., D, M., E, V. C., WJ, H., L, W., DY, O., T, O., M, M., AC, B., G, G., M, L., MLL, M., EC, S., LY, C., SH, R., N, V., I, X., J, T., & investigators, M. (2026). Perioperative durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable gastric and gastro-oesophageal junction adenocarcinoma (MATTERHORN): final results of overall survival and event-free survival by pathological response in a global, randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.. Lancet (London, England). https://doi.org/10.1016/s0140-6736(26)01254-7

Source records

pubmed · retrieved 2026-09-25T16:32:22.410Z